Tech Company Financing Transactions
Human Immunology Biosciences Funding Round
Human Immunology Biosciences, operating out of San Francisco,, secured $120 million from Arch Venture Partners, Jeito Capital and Monograph Capital.
Transaction Overview
Company Name
Announced On
11/1/2022
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Proceeds Purpose
The company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). HI-Bio is leading clinical immunology into its next chapter with more targeted therapies that target cellular drivers of disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Tower Place 16th Fl South
San Francisco,, CA 94080
USA
San Francisco,, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Travis Murdoch
Browse more venture capital transactions:
Prev: 11/1/2022: Cover Genius venture capital transaction
Next: 11/1/2022: AMP venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs